Targets › E4ORF1
1 program from 1 company in 2 trials: 2 Phase 1; Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: the race on E4ORF1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Weill Medical College of Cornell University | E-CEL UVEC cells (AB-207) Allogeneic pro-survival gene-transduced human umbilical vein endothelial cells | E4ORF1 | Phase 1 | Chronic Anal Fissure; Anal Fistula | Dec 2026 |
Chronic Anal Fissure (1) Anal Fistula (1)
other (1)
Weill Medical College of Cornell University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.